WooGene B&G Co Ltd

WooGene B&G Co Ltd has a debt-to-equity ratio of 1.02, indicating a balanced capital structure with liabilities slightly exceeding equity. The company maintains a current ratio of 1.2, suggesting moderate liquidity, though its free cash flow is negative at -2.19 billion KRW, and capital expenditures are -2.81 billion KRW, indicating ongoing investment in operations. Profitability metrics are weak, with a return on equity of -5.76% and a return on assets of -1.63%, both significantly below the industry median for pharmaceuticals. The company reported a net loss of 1.77 billion KRW, despite generating 54.76 billion KRW in revenue, highlighting challenges in cost control and pricing power. The company operates through two segments: Manufacturing of Animal Drugs and Import Product of Animal Drugs. Revenue is concentrated in these two segments, with no disclosed geographic breakdown. The import segment includes swine diarrhea virus vaccines, which may be sensitive to regional livestock health trends. Growth appears constrained, with no disclosed revenue growth rates or forward-looking guidance. The company's operating cash flow of 3.84 billion KRW contrasts with its negative net income, suggesting non-cash expenses or asset write-downs are impacting profitability. Risk factors include liquidity concerns, as net cash is negative after subtracting total debt. The company has low dilution risk, with no recent share issuance or shelf registration activity reported. However, the negative net income and high debt load could pressure liquidity if cash flow does not improve. Recent events include the 2026-04 sanctions on certain animal health products, which may affect the import segment. No recent filings or transcripts have been disclosed that provide further insight into the company's strategic direction or operational performance.